Skip Navigation



JAC Advance Access published online on February 24, 2006
Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkl046
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
57/4/771    most recent
dkl046v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Rodriguez-Villalobos, H.
Right arrow Articles by Struelens, M. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rodriguez-Villalobos, H.
Right arrow Articles by Struelens, M. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2006. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oxfordjournals.org
Received August 29, 2005
Revised February 2, 2006
Accepted February 2, 2006

Brief report

In vitro activity of temocillin against extended spectrum {beta}-lactamase-producing Escherichia coli

Hector Rodriguez-Villalobos 1 *, Vincent Malaviolle 1, Joëlle Frankard 1, Ricardo de Mendonça 1, Claire Nonhoff 1, and Marc J. Struelens 1

1 Microbiology Department, Erasme Hospital-Université Libre de Bruxelles, Brussels, Belgium

* To whom correspondence should be addressed.
Hector Rodriguez-Villalobos, E-mail: hrodrigu{at}ulb.ac.be


  Abstract

Objectives: Temocillin is a semi-synthetic 6-{alpha}-methoxy derivative of ticarcillin. It is highly stable to most bacterial {beta}-lactamases. However, data concerning its activity against extended-spectrum {beta}-lactamase (ESBL)-producing Enterobacteriaceae are limited. We have analysed the in vitro activity of temocillin against clinical isolates of ESBL-producing Escherichia coli over the past 4 years in a university hospital in Brussels, Belgium.

Methods: Strains were screened for ESBL production using the double-disc synergy test. The MIC of 12 antimicrobial agents was determined for ESBL-producing E. coli isolates (n = 162) using the agar dilution method. ESBLs were characterized by isoelectric focusing; multiplex PCR for bla genes of the SHV, TEM and CTX-M families; and DNA sequencing.

Results: ESBL-producing E. coli isolates harboured CTX-M+TEM (35%), TEM alone (44%), CTX-M alone (6%), CTX-M+SHV (2%) and other ESBL combinations (10%). The proportion of temocillin-susceptible isolates was 92%, with MIC50 and MIC90 values of 8 and 32 mg/L, respectively. Co-resistance to ciprofloxacin and co-trimoxazole in ESBL-producing E. coli was frequent (39%). The proportion of isolates not susceptible to aminoglycosides was 55, 37 and 4% for tobramycin, gentamicin and amikacin, respectively. The proportion of isolates not susceptible to ceftazidime, cefotaxime, cefepime and piperacillin/tazobactam was 70, 52, 37 and 11%, respectively. No resistance to meropenem was observed. The proportion of strains exhibiting resistance to temocillin by year was stable over the study period.

Conclusions: These data indicate good in vitro activity of temocillin against multiresistant ESBL-producing E. coli. Prospective clinical studies are necessary to examine temocillin's potential role in the treatment of non-complicated infections caused by ESBL-producing E. coli.

Keywords: ESBLs; E. coli; antimicrobial susceptibility.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
J. M. Adams-Haduch, B. A. Potoski, H. E. Sidjabat, D. L. Paterson, and Y. Doi
Activity of Temocillin against KPC-Producing Klebsiella pneumoniae and Escherichia coli
Antimicrob. Agents Chemother., June 1, 2009; 53(6): 2700 - 2701.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
H. Rodriguez-Villalobos, A. Cardentey-Reyes, C. Thiroux, C. Nonhoff, and M. J. Struelens
Comparison of four commercial methods for determining temocillin susceptibility of Escherichia coli
J. Antimicrob. Chemother., April 1, 2009; 63(4): 832 - 834.
[Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. M. Livermore and P. M. Tulkens
Temocillin revived
J. Antimicrob. Chemother., February 1, 2009; 63(2): 243 - 245.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
R. De Jongh, R. Hens, V. Basma, J. W. Mouton, P. M. Tulkens, and S. Carryn
Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection
J. Antimicrob. Chemother., February 1, 2008; 61(2): 382 - 388.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
D. M. Livermore, R. Canton, M. Gniadkowski, P. Nordmann, G. M. Rossolini, G. Arlet, J. Ayala, T. M. Coque, I. Kern-Zdanowicz, F. Luzzaro, et al.
CTX-M: changing the face of ESBLs in Europe
J. Antimicrob. Chemother., February 1, 2007; 59(2): 165 - 174.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.